RU2730011C2 - Адъюванты на масляной основе - Google Patents

Адъюванты на масляной основе Download PDF

Info

Publication number
RU2730011C2
RU2730011C2 RU2016109925A RU2016109925A RU2730011C2 RU 2730011 C2 RU2730011 C2 RU 2730011C2 RU 2016109925 A RU2016109925 A RU 2016109925A RU 2016109925 A RU2016109925 A RU 2016109925A RU 2730011 C2 RU2730011 C2 RU 2730011C2
Authority
RU
Russia
Prior art keywords
adjuvant
present
amount
vaccine
per dose
Prior art date
Application number
RU2016109925A
Other languages
English (en)
Russian (ru)
Other versions
RU2016109925A3 (https=
RU2016109925A (ru
Inventor
Пол Джозеф Доминовски
Лорен ВИЛЬМЕС
Денис Л. ФОСС
Каори МОР
Гильермо ГАЛЛО
Джон Морган ХАРДХАМ
Ричард Ли КРЕБС
Сандра Энн Мари ЛАЙТЛИ
Суман МАХАН
Сангита Медиратта
Дункан МВАНГИ
Шарат К. РАЙ
Сара А. СЭЛМОН
Шаунак ВОРА
Майкл Кристофер ФОНТЭЙН
Дэвид Джордж Эмсли СМИТ
Джули Лидиа ФИТЦПАТРИК
Уильям ДОНАЧИ
Анита Дорота ЯГЛАРЖ
Original Assignee
Зоэтис Сервисиз Ллс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Зоэтис Сервисиз Ллс filed Critical Зоэтис Сервисиз Ллс
Publication of RU2016109925A publication Critical patent/RU2016109925A/ru
Publication of RU2016109925A3 publication Critical patent/RU2016109925A3/ru
Application granted granted Critical
Publication of RU2730011C2 publication Critical patent/RU2730011C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/012—Coccidia antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/118—Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56944—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/315—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Streptococcus (G), e.g. Enterococci
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
RU2016109925A 2013-09-19 2014-09-19 Адъюванты на масляной основе RU2730011C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361879959P 2013-09-19 2013-09-19
US61,879,959 2013-09-19
PCT/US2014/056512 WO2015042369A2 (en) 2013-09-19 2014-09-19 Oil-based adjuvants

Related Child Applications (3)

Application Number Title Priority Date Filing Date
RU2019128164A Division RU2816851C2 (ru) 2013-09-19 2014-09-19 Адъюванты на масляной основе
RU2020113283A Division RU2020113283A (ru) 2014-09-19 2014-09-19 Адъюванты на масляной основе
RU2019128165A Division RU2816849C2 (ru) 2013-09-19 2014-09-19 Адъюванты на масляной основе

Publications (3)

Publication Number Publication Date
RU2016109925A RU2016109925A (ru) 2017-10-24
RU2016109925A3 RU2016109925A3 (https=) 2018-04-02
RU2730011C2 true RU2730011C2 (ru) 2020-08-14

Family

ID=51663499

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016109925A RU2730011C2 (ru) 2013-09-19 2014-09-19 Адъюванты на масляной основе

Country Status (16)

Country Link
US (6) US10117921B2 (https=)
EP (2) EP3049105B1 (https=)
JP (7) JP6586083B2 (https=)
KR (4) KR101943171B1 (https=)
CN (4) CN109675026A (https=)
AU (5) AU2014321369B2 (https=)
BR (1) BR112016005948A2 (https=)
CA (4) CA2924526A1 (https=)
CL (3) CL2016000650A1 (https=)
MX (3) MX386918B (https=)
NZ (3) NZ757210A (https=)
PH (1) PH12016500456A1 (https=)
RU (1) RU2730011C2 (https=)
UA (2) UA130246C2 (https=)
WO (3) WO2015042449A2 (https=)
ZA (3) ZA201601840B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2848210C1 (ru) * 2024-12-11 2025-10-16 Федеральное государственное бюджетное учреждение "Федеральный центр охраны здоровья животных" ФГБУ "ВНИИЗЖ" Масляный адъювант для изготовления вакцин ветеринарного назначения

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201505086QA (en) * 2012-12-28 2015-07-30 Boehringer Ingelheim Vetmed Immunogenic composition comprising mycoplasma antigens
UA130246C2 (uk) * 2013-09-19 2025-12-31 Зоетіс Сервісіз Ллс Ад'ювант на основі олії
EP4241853B1 (en) * 2013-11-26 2026-02-11 Zoetis Services LLC Compositions for induction of immune response
SI3166634T1 (sl) 2014-07-11 2021-11-30 Zoetis Services Llc Sestave novih cepiv za virus prašičje epidemične diareje
CN115317600A (zh) 2015-01-16 2022-11-11 硕腾服务有限责任公司 口蹄疫疫苗
AU2016211916B2 (en) * 2015-01-27 2018-10-18 3M Innovative Properties Company Alum-containing coating formulations for microneedle vaccine patches
US10456459B2 (en) * 2015-07-20 2019-10-29 Zoetis Services Llc Liposomal adjuvant compositions
EP3325015B1 (en) * 2015-07-20 2021-05-12 Zoetis Services LLC Liposomal adjuvant compositions
CN106421775B (zh) * 2015-08-12 2020-12-01 普莱柯生物工程股份有限公司 一种疫苗用佐剂及含该佐剂的疫苗组合物和其应用
WO2017123201A1 (en) 2016-01-11 2017-07-20 Zoetis Services Llc Novel cross protective vaccine compositions for porcine epidemic diarrhea virus
EP3417049B1 (en) 2016-02-15 2023-08-16 Hipra Scientific, S.L.U. Streptococcus uberis extract as an immunogenic agent
US11013798B2 (en) 2016-03-21 2021-05-25 South Dakota Board Of Regents Orf virus-based platform for vaccine delivery
KR20210068602A (ko) 2016-06-02 2021-06-09 조에티스 서비시즈 엘엘씨 감염성 기관지염에 대한 백신
EP3558350A1 (en) * 2016-12-22 2019-10-30 Intervet International B.V. Eimeria vaccine with improved efficacy
KR101996538B1 (ko) * 2017-02-13 2019-07-04 단디바이오사이언스 주식회사 이미다조퀴놀린계열 물질을 포함하는 나노에멀젼 및 이의 용도
GB201703529D0 (en) 2017-03-06 2017-04-19 Cambridge Entpr Ltd Vaccine composition
GB201718251D0 (en) * 2017-11-03 2017-12-20 Univ Sydney Vaccine Compositions
KR20230039766A (ko) * 2017-12-20 2023-03-21 조에티스 서비시즈 엘엘씨 Hendra 및 Nipah 바이러스 감염을 대비한 백신
CN108553479A (zh) * 2018-04-03 2018-09-21 南京大学 阳离子修饰的琼脂糖和核酸药物组合物及制备方法和应用
CN108853493A (zh) * 2018-07-26 2018-11-23 中国人民解放军陆军军医大学 麦冬皂苷d及其纳米乳在制备疫苗佐剂中的应用
WO2020023950A1 (en) 2018-07-27 2020-01-30 Research Development Foundation Chimeric immunogenic polypeptides
CN110967482B (zh) * 2018-09-30 2023-04-07 重庆市畜牧科学院 一种山羊化脓隐秘杆菌感染检测试剂盒及其检测方法
CN109675028A (zh) * 2019-03-01 2019-04-26 龙阔（苏州）生物工程有限公司 疫苗佐剂及其制备方法和应用及猪繁殖与呼吸综合征疫苗
KR102285977B1 (ko) 2019-03-15 2021-08-05 대한민국 오일 에멀젼과 병용 투여 가능한 면역증강용 보조물질 및 이를 포함하는 구제역 백신 조성물
CN114514238A (zh) * 2019-07-12 2022-05-17 研究发展基金会 埃立克体疫苗和免疫原性组合物
US12514917B2 (en) * 2019-07-15 2026-01-06 South Dakota Board Of Regents Senecavirus A virus strains and immunogenic compositions therefrom
KR20220041142A (ko) * 2019-07-30 2022-03-31 피브로 애니멀 헬스 코포레이션 조류에 점막 투여하기 위한 조성물
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
TWI884296B (zh) * 2020-08-11 2025-05-21 美商碩騰服務公司 抗冠狀病毒疫苗
CN112611864B (zh) * 2020-12-03 2024-03-12 重庆市畜牧科学院 筛分病菌模型的系统及筛分方法
JP2024500360A (ja) * 2020-12-11 2024-01-09 エイシーエム バイオラブズ プライベート リミテッド 関連づけられた抗原および関連づけられたアジュバントを有する２つのポリマーソーム集団を投与することによる、Ｔｈ１／Ｔｈ２免疫応答の調整方法
CN114015621B (zh) * 2021-12-13 2022-04-26 云南农业大学 一种降解α-茄碱的谷氨酸杆菌GH202103菌株及其制备方法和应用
JP2026509384A (ja) * 2023-03-21 2026-03-18 インディアン カウンシル オブ アグリカルチュラル リサーチ 口蹄疫の制御のためのワクチン組成物および方法
US12226468B2 (en) 2023-06-26 2025-02-18 Research Development Foundation Immunoreactive peptides
CN116747312B (zh) * 2023-07-21 2025-08-08 辽宁成大生物股份有限公司 一种疫苗冻干保护剂、制剂及制备方法
CN119925590A (zh) * 2025-04-08 2025-05-06 北京华诺泰生物医药科技有限公司 一种mpl复合佐剂及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004052A1 (en) * 1989-09-22 1991-04-04 Peptide Technology Ltd. Vaccines
US20040009897A1 (en) * 2002-02-14 2004-01-15 Sokoll Kenneth K. Stabilized synthetic immunogen delivery system
US20040180060A1 (en) * 2003-03-12 2004-09-16 Wyeth Adjuvanted bovine vaccines

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ221306A (en) 1986-08-15 1990-02-26 Commw Scient Ind Res Org 2-component immunoadjuvant comprising a mycobacterial free immunoadjuvant oil and a polycationic polyelectrolyte immunoadjuvant and vaccines thereof
EP0273512B1 (en) 1986-12-19 1991-02-27 Duphar International Research B.V Stabilised adjuvant suspension comprising dimethyl dioctadecyl ammonium bromide
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
RU1615918C (ru) 1989-05-22 1995-07-09 Всероссийский научно-исследовательский институт защиты животных Адъювант
ZA936095B (en) 1992-08-21 1994-03-14 Univ Melbourne Cytokine applications.
US6764682B1 (en) 1994-06-16 2004-07-20 Aventis Pasteur Limited Adjuvant compositions containing more than one adjuvant
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6846489B1 (en) 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
ZA978434B (en) * 1996-09-27 1998-03-26 Akzo Nobel Nv Inactivated vaccines.
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
US20100267012A1 (en) * 1997-11-04 2010-10-21 Bergeron Michel G Highly conserved genes and their use to generate probes and primers for detection of microorganisms
EP0855184A1 (en) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
DK1005368T3 (da) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
CA2289253A1 (en) 1997-04-30 1998-11-05 Merieux Oravax Anti-helicobacter vaccine composition for use by the subdiaphragmatic systemic route, and combined mucosal/parenteral immunization method
AU733310C (en) 1997-05-14 2001-11-29 University Of British Columbia, The High efficiency encapsulation of charged therapeutic agents in lipid vesicles
EP1003850B1 (en) 1997-06-06 2009-05-27 The Regents of the University of California Inhibitors of dna immunostimulatory sequence activity
JP2002514397A (ja) 1998-05-14 2002-05-21 コーリー ファーマシューティカル ゲーエムベーハー ＣｐＧオリゴヌクレオチドを用いる造血調節の方法
SI1077722T1 (sl) 1998-05-22 2007-02-28 Ottawa Health Research Inst Metode in produkti za induciranje sluznicne imunosti
US20040247662A1 (en) 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
PT1104306E (pt) 1998-08-10 2006-05-31 Antigenics Inc Composicoes de cpg e adjuvantes de saponina e seus metodos
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
EP1156781B1 (en) 1999-02-26 2005-06-08 Chiron Corporation Microemulsions with adsorbed macromolecules and microparticles
AU4188100A (en) 1999-04-08 2000-11-14 Gregory M. Glenn Dry formulation for transcutaneous immunization
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
PT1187629E (pt) 1999-04-19 2005-02-28 Glaxosmithkline Biolog Sa Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
EP1177439B1 (en) 1999-04-29 2004-09-08 Coley Pharmaceutical GmbH Screening for immunostimulatory dna functional modifiers
AU2001227889A1 (en) 2000-01-14 2001-07-24 The United States of America, represented by The Secretary, Department of Health & Human Services Oligodeoxynucleotide and its use to induce an immune response
US20010044416A1 (en) 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
JP5025871B2 (ja) 2000-02-21 2012-09-12 エイチ．リュンドベック エイ／エス アミロイドの新規なダウン−レギュレート方法
AU5736601A (en) 2000-05-01 2001-11-12 Hybridon Inc Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
AU2002244337B2 (en) * 2000-10-18 2005-08-11 Glaxosmithkline Biologicals S.A. Vaccines
GB0025577D0 (en) 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
CA2881568C (en) * 2000-10-27 2019-09-24 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from streptococcus groups a & b
ES2307568T3 (es) 2000-12-08 2008-12-01 Coley Pharmaceutical Gmbh Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
US7244438B2 (en) 2001-01-05 2007-07-17 Intercell Ag Uses for polycationic compounds
US7713942B2 (en) 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
CA2439111A1 (en) 2001-04-05 2002-10-17 Chiron Corporation Mucosal boosting following parenteral priming
US7105495B2 (en) 2001-04-30 2006-09-12 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
WO2002094845A2 (en) 2001-05-21 2002-11-28 Intercell Ag Method for stabilising of nucleic acids
EP1395262A4 (en) 2001-06-15 2006-04-12 Ribapharm Corp NUCLEOSIDE-VACCINE-ADJUVANTS
WO2003003941A2 (en) 2001-07-02 2003-01-16 Pfizer Products Inc. One dose vaccination with mycoplasma hyopneumoniae
WO2003004051A2 (en) 2001-07-02 2003-01-16 Pfizer Products Inc. Mycoplasma hyopneumoniae vaccine and methods for reducing mycoplasma bovis pneumonia in cattle
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
CA2456193A1 (en) 2001-08-03 2003-03-27 Medarex, Inc. Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies
US20030133988A1 (en) 2001-08-07 2003-07-17 Fearon Karen L. Immunomodulatory compositions, formulations, and methods for use thereof
US20030138434A1 (en) 2001-08-13 2003-07-24 Campbell Robert L. Agents for enhancing the immune response
ATE411054T1 (de) 2001-08-17 2008-10-15 Coley Pharm Gmbh Kombinations-motif-immunstimulierende oligonukleotide mit verbesserter wirkung
IL159145A0 (en) 2001-08-28 2004-06-01 Pfizer Prod Inc Mycoplasma bovis challenge model, methods for administering m. bovis and methods for inducing pneumonic lung lesions
DE60234375D1 (de) 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
US20030119774A1 (en) 2001-09-25 2003-06-26 Marianna Foldvari Compositions and methods for stimulating an immune response
GB0123580D0 (en) 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
US20050238660A1 (en) 2001-10-06 2005-10-27 Babiuk Lorne A Cpg formulations and related methods
US7276489B2 (en) 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
EP1441763A2 (en) 2001-11-07 2004-08-04 Inex Pharmaceuticals Corp. Mucosal adjuvants comprising an oligonucleotide and a cationic lipid
AU2002358616A1 (en) 2001-12-07 2003-06-17 Intercell Ag Immunostimulatory oligodeoxynucleotides
WO2003066649A1 (en) 2002-02-04 2003-08-14 Biomira Inc. Immunostimulatory, covalently lipidated oligonucleotides
EP1476456A4 (en) 2002-02-19 2007-06-20 Syntherica Corp COMPOSITIONS AND METHOD FOR SUBROGEN-ANTIBODY MODULATION OF AN IMMUNE RESPONSE AND TRANSPORT
EP3006043B1 (en) 2002-04-04 2019-05-29 Zoetis Belgium S.A. Immunostimulatory g,u-containing oligoribonucleotides
WO2003089590A2 (en) 2002-04-16 2003-10-30 Vaxin, Inc. TRANSIENT AND/OR PERMANENT MODIFICATION OF SEXUAL BEHAVIOR AND/OR FERTILITY USING RECOMBINANT CHIMERIC GnRH
KR101092043B1 (ko) 2002-04-22 2011-12-12 바이오니취 라이프 사이언시즈 인코포레이티드 올리고뉴클레오티드 조성물 및 면역 반응 조절시 이의 용도
KR100456681B1 (ko) 2002-05-22 2004-11-10 주식회사 대웅 박테리아의 염색체 ｄｎａ 파쇄물과 비독성리포폴리사카라이드를 포함하는 면역강화 및 조절 조성물
CA2487452A1 (en) 2002-05-28 2003-12-04 Robinson Ramirez-Pineda A method for generating antigen-presenting cells
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
US20040009949A1 (en) 2002-06-05 2004-01-15 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids
SE0201701D0 (sv) 2002-06-05 2002-06-05 Gotovax Ab Treatment of epithelial tumors and infections
EP1575504A4 (en) 2002-08-01 2009-11-04 Us Gov Health & Human Serv METHOD FOR THE TREATMENT OF INFLAMMATORY ARTHROPATHIES WITH SUPPRESSORS OF THE CPG OLIGONUCLEOTIDES
TWI314134B (en) 2002-11-05 2009-09-01 James Hardie Int Finance Bv Calcium silicate hydrate and the method for producing the same
MXPA05008051A (es) 2003-01-29 2005-09-21 Pfizer Prod Inc Vacunas caninas contra bordetella bronchiseptica.
AU2004224761A1 (en) 2003-03-26 2004-10-07 Cytos Biotechnology Ag HIV-peptide-carrier-conjugates
AU2004226591B2 (en) 2003-04-04 2009-06-04 Zoetis Services Llc Microfluidized oil-in-water emulsions and vaccine compositions
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
KR20110132416A (ko) 2004-04-05 2011-12-07 화이자 프로덕츠 인코포레이티드 미세유체화된 수중유 유화액 및 백신 조성물
US7749520B2 (en) 2004-07-07 2010-07-06 Statens Serum Institut Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
JP4987704B2 (ja) * 2004-07-07 2012-07-25 スタテンス セールム インスティトゥート 糖脂質を用いた、脂質系アジュバント製剤を安定化する組成物及び方法
WO2006106424A2 (en) 2005-04-07 2006-10-12 Pharmacia & Upjohn Company Llc Formulations and process for production of bordetella bronchiseptica p68 antigen and vaccines
CA2634888C (en) 2006-01-26 2016-06-21 Pfizer Products Inc. Novel glycolipid adjuvant compositions
WO2007125940A1 (ja) * 2006-04-25 2007-11-08 Kyowa Hakko Kogyo Co., Ltd. ネコノミ成虫由来ポリペプチド
PT2078080E (pt) * 2006-09-27 2015-09-18 Coley Pharm Gmbh Análogos dos oligonucleotídeos cpg que contêm análogos t hidrofóbicos com atividade imunoestimulante potenciada
US20080292663A1 (en) 2007-05-22 2008-11-27 Gerber Jay D Adjuvant compositions and methods for delivering vaccines
CL2008001806A1 (es) * 2007-06-20 2008-09-05 Wyeth Corp Composicion de vacuna en emulsion agua en aceite que comprende un antigeno y un adyuvante en la fase acuosa; y metodo de elaboracion.
EP2023143A1 (en) * 2007-08-06 2009-02-11 Boehringer Ingelheim Vetmedica Gmbh Immunogenic streptococcus proteins
US8703153B2 (en) * 2008-06-16 2014-04-22 Prokarium Ltd. Salmonella vectored vaccines against Chlamydia and methods of use
ES2569907T3 (es) * 2008-06-27 2016-05-13 Zoetis Services Llc Composiciones adyuvantes novedosas
GB0818231D0 (en) * 2008-10-06 2008-11-12 Univ Nottingham Composition
CN101721698B (zh) 2008-10-24 2014-04-02 法罗斯疫苗公司 抗口蹄疫疫苗组合物及其制备和应用
CA2753567C (en) 2009-02-27 2019-12-31 Toray Industries, Inc. Immunogenic antigen-adjuvant microparticle complex
JP2013525271A (ja) * 2010-03-12 2013-06-20 チルドレンズ メディカル センター コーポレーション 免疫原およびそのスクリーニング方法
EP2575878B1 (en) * 2010-05-28 2018-06-13 Zoetis Belgium S.A. Vaccines comprising cholesterol and cpg as sole adjuvant-carrier molecules
US8765141B2 (en) * 2010-07-01 2014-07-01 The United States Of America, As Represented By The Secretary Of Agriculture Development of a marker foot and mouth disease virus vaccine candidate that is attenuated in the natural host
CN101954080B (zh) 2010-09-21 2013-11-06 中国农业科学院兰州兽医研究所 一种猪口蹄疫苗用的复合分子型佐剂及其制造方法
PL2670432T3 (pl) 2011-02-04 2021-10-11 Zoetis Services Llc Kompozycje immunogenne Bordetella bronchiseptica
EP2707025B8 (en) * 2011-05-13 2017-08-23 Zoetis Services LLC Hendra and nipah virus g glycoprotein immunogenic compositions
US20130309273A1 (en) 2012-05-17 2013-11-21 Kimberly Hassett Thermostable Vaccine Compositions and Methods of Preparing Same
GB201111183D0 (en) 2011-06-30 2011-08-17 Animal Health Inst Peptide
MX382968B (es) * 2012-11-16 2025-03-12 United Biomedical Inc Vacuna de emergencia basada en péptidos sintéticos contra la fiebre aftosa.
CN103083663B (zh) 2013-02-04 2014-12-10 江苏省农业科学院 一种免疫增强剂、灭活疫苗及其制备方法
BR112015021755A2 (pt) * 2013-03-07 2017-07-18 Kane Biotech Inc composições antimicrobianas e antibiofilmes e métodos de aplicação das mesmas
US10357470B2 (en) * 2013-03-07 2019-07-23 Kane Biotech Inc. Antimicrobial-antibiofilm compositions and methods of use thereof
CN105209067A (zh) 2013-03-26 2015-12-30 皮尔布赖特研究所 稳定的fmdv衣壳
HK1224177A1 (zh) * 2013-09-05 2017-08-18 硕腾服务有限责任公司 Hendra和nipah病毒g糖蛋白免疫原性組合物
UA130246C2 (uk) * 2013-09-19 2025-12-31 Зоетіс Сервісіз Ллс Ад'ювант на основі олії
CN104013955B (zh) * 2014-06-18 2016-02-24 中国科学院过程工程研究所 一种不含表面活性剂的水包油乳液及其用途
RU2593718C1 (ru) 2015-03-16 2016-08-10 Федеральное государственное бюджетное учреждение "Федеральный центр охраны здоровья животных" (ФГБУ "ВНИИЗЖ") Вакцина инактивированная эмульсионная против ящура типов а, о, азия-1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004052A1 (en) * 1989-09-22 1991-04-04 Peptide Technology Ltd. Vaccines
US20040009897A1 (en) * 2002-02-14 2004-01-15 Sokoll Kenneth K. Stabilized synthetic immunogen delivery system
US20040180060A1 (en) * 2003-03-12 2004-09-16 Wyeth Adjuvanted bovine vaccines

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Gonzalez D.D. et al. Evaluation of a bovine rotavirus VP6 vaccine efficacy in the calf model of infection and disease.// Veterinary Immunology and Immunopathology, 2010, 137, с. 155-160. PMID: 20546933. *
Gonzalez D.D. et al. Evaluation of a bovine rotavirus VP6 vaccine efficacy in the calf model of infection and disease.// Veterinary Immunology and Immunopathology, 2010, 137, с. 155-160. PMID: 20546933. Robert W. Fulton. et al. Bovine coronavirus (BCV) infections in transported commingled beef cattle and sole-source ranch calves.// Can J Vet Res, 2011 июль, 75 (3), с.191-199. PMID: 22210995. Duchet-Suchaux M. Protective antigens against enterotoxigenic Escherichia coli O101:K99, F41 in the infant mouse diarrhea model. // Infect Immun, 1988, May,56 (5), с.1364-70. PMID: 2895746. *
PMID: 22210995. Duchet-Suchaux M. Protective antigens against enterotoxigenic Escherichia coli O101:K99, F41 in the infant mouse diarrhea model. // Infect Immun, 1988, May,56 (5), с.1364-70. PMID: 2895746. *
Robert W. Fulton. et al. Bovine coronavirus (BCV) infections in transported commingled beef cattle and sole-source ranch calves.// Can J Vet Res, 2011 июль, 75 (3), с.191-199. *
Susan L. Baldwin et al. The Importance of Adjuvant Formulation in the Development of a Tuberculosis Vaccine.// J Immunol, 2012, том 188, выпуск 5 с.2189-2197. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2848210C1 (ru) * 2024-12-11 2025-10-16 Федеральное государственное бюджетное учреждение "Федеральный центр охраны здоровья животных" ФГБУ "ВНИИЗЖ" Масляный адъювант для изготовления вакцин ветеринарного назначения

Also Published As

Publication number Publication date
US10117921B2 (en) 2018-11-06
CN109675026A (zh) 2019-04-26
US10953080B2 (en) 2021-03-23
US11701415B2 (en) 2023-07-18
JP2019167356A (ja) 2019-10-03
AU2020202147B2 (en) 2022-12-08
AU2025202708A1 (en) 2025-05-08
WO2015042369A3 (en) 2015-07-02
AU2014321369B2 (en) 2020-04-16
CL2018000319A1 (es) 2018-06-08
AU2020202147A1 (en) 2020-04-16
KR20180024030A (ko) 2018-03-07
US20160193318A1 (en) 2016-07-07
NZ757210A (en) 2022-12-23
PH12016500456A1 (en) 2016-05-16
EP3049105B1 (en) 2020-12-30
UA130246C2 (uk) 2025-12-31
CA2924526A1 (en) 2015-03-26
KR102257743B1 (ko) 2021-05-28
CA3174897C (en) 2025-10-07
JP2022121437A (ja) 2022-08-19
JP6586083B2 (ja) 2019-10-02
JP2021073191A (ja) 2021-05-13
MX2021012346A (es) 2021-11-04
BR112016005948A2 (pt) 2017-09-26
CN109675025A (zh) 2019-04-26
CN105764525A (zh) 2016-07-13
RU2016109925A3 (https=) 2018-04-02
US20240000913A1 (en) 2024-01-04
ZA201903401B (en) 2024-09-25
AU2022275399A1 (en) 2023-01-05
KR20160057465A (ko) 2016-05-23
UA121200C2 (uk) 2020-04-27
CL2018000320A1 (es) 2018-06-08
US20190038737A1 (en) 2019-02-07
RU2016109925A (ru) 2017-10-24
CN109675029A (zh) 2019-04-26
EP3049105A2 (en) 2016-08-03
CA3005608A1 (en) 2015-03-26
MX386918B (es) 2025-03-19
KR20190009840A (ko) 2019-01-29
KR101943171B1 (ko) 2019-01-29
CL2016000650A1 (es) 2016-11-18
JP7751438B2 (ja) 2025-10-08
MX2021005619A (es) 2021-08-11
RU2019128165A (ru) 2019-10-10
JP2020007341A (ja) 2020-01-16
ZA201903400B (en) 2024-09-25
ZA201601840B (en) 2022-09-28
US10744192B2 (en) 2020-08-18
AU2022268311B2 (en) 2025-01-23
CA3005608C (en) 2020-06-30
MX2016003658A (es) 2016-06-24
RU2019128164A (ru) 2019-10-10
JP7189410B2 (ja) 2022-12-14
CA3174897A1 (en) 2015-03-26
JP6667704B2 (ja) 2020-03-18
AU2014321369A1 (en) 2016-03-17
WO2015042449A3 (en) 2015-10-08
NZ733383A (en) 2022-12-23
US20150140034A1 (en) 2015-05-21
US20250108103A1 (en) 2025-04-03
AU2022268311A1 (en) 2022-12-15
WO2015042423A2 (en) 2015-03-26
JP7675048B2 (ja) 2025-05-12
US20210170013A1 (en) 2021-06-10
JP2022001581A (ja) 2022-01-06
JP7181847B2 (ja) 2022-12-01
EP3046580A2 (en) 2016-07-27
US12121576B2 (en) 2024-10-22
WO2015042449A2 (en) 2015-03-26
KR20200039025A (ko) 2020-04-14
NZ717594A (en) 2017-07-28
WO2015042423A3 (en) 2016-07-28
WO2015042369A2 (en) 2015-03-26
JP2016534977A (ja) 2016-11-10
AU2022275399B2 (en) 2025-05-08
JP2018203770A (ja) 2018-12-27
CA3060664A1 (en) 2015-03-26

Similar Documents

Publication Publication Date Title
JP7675048B2 (ja) 油性アジュバント
RU2816849C2 (ru) Адъюванты на масляной основе
RU2816851C2 (ru) Адъюванты на масляной основе
CA3276160A1 (en) Water-in-oil emulsions comprising immunostimulatory oligonucleotides